Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
INSULET CORP
Report date April 28, 2025 · Filed April 30, 2025
Section 16 reporting ended · disclosed 2025-04-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 61,247 |
Reported balance
After 2025-04-28 transaction · row 1
1 source rowRow 1 · 2025-04-28 · Tax withholding · Disposed 3,587 · Balance 61,247 F1: This transaction represents the withholding of shares received upon the vesting of restricted stock units to cover the associated tax obligations. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction represents the withholding of shares received upon the vesting of restricted stock units to cover the associated tax obligations.
RESMED INC
Report date June 30, 2022 · Filed August 18, 2022
Section 16 reporting ended · disclosed 2022-08-18. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 28, 2025 Filed Apr 30, 2025 20:25 UTC | INSULET CORP PODD · Entity 3516 | Tax withholdingCommon Stock | 3,587 | $259.52 | $930,898.24 |
DisclosureSEC source: 0001127602-25-012804 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · Former President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,247 F1 · shares: This transaction represents the withholding of shares received upon the vesting of restricted stock units to cover the associated tax obligations. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 21:13 UTC | INSULET CORP PODD · Entity 3516 | Tax withholdingCommon Stock | 1,160 | $272.27 | $315,833.20 |
DisclosureSEC source: 0001127602-25-007870 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,834 F1 · shares: This transaction represents the withholding of shares received upon the vesting of restricted stock units to cover the associated tax obligations. Read SEC document |
| February 27, 2025 Filed Feb 28, 2025 21:19 UTC | INSULET CORP PODD · Entity 3516 | Tax withholdingCommon Stock | 2,074 | $267.09 | $553,944.66 |
DisclosureSEC source: 0001127602-25-007245 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,994 F1 · shares: This transaction represents the withholding of shares received upon the vesting of restricted stock units to cover the associated tax obligations. Read SEC document |
| February 25, 2025 Filed Feb 26, 2025 21:22 UTC | INSULET CORP PODD · Entity 3516 | GrantEmployee Stock Option (Right to Buy) · Derivative | 19,458 | $0.00 Strike: $266.68 | $0.00 |
DisclosureSEC source: 0001127602-25-006859 · form4.xml · derivative · entry 2 Hollingshead James · CIK 0001570610 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,458 Underlying: Common Stock · 19,458 shares Expires 2035-02-25 F2 · derivative.exercise_date: Annual Non-Qualified Stock Option ("Option") Award. The Options become exercisable in substantially equal installments on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| February 25, 2025 Filed Feb 26, 2025 21:22 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 7,687 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-006859 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,068 F1 · shares: Annual Restricted Stock Unit ("RSU") award. RSUs vest in equal installments on each of the first, second and third anniversaries of the grant date and are settled in shares of common stock on a one-for-one basis. Read SEC document |
| February 17, 2025 Filed Feb 19, 2025 21:08 UTC | INSULET CORP PODD · Entity 3516 | Tax withholdingCommon Stock | 18,019 | $280.56 | $5,055,410.64 |
DisclosureSEC source: 0001127602-25-005472 · form4.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,381 F3 · shares: This transaction represents the withholding of shares upon the vesting of performance share units to cover the associated tax obligations. Read SEC document |
| February 17, 2025 Filed Feb 19, 2025 21:08 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 36,671 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-005472 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,400 F1 · shares: Represents shares issued upon the satisfaction of performance criteria related to Performance Share Units ("PSUs"). The PSUs were settled in shares of common stock on a one-for-one basis. F2 · balance_after: Includes 130 shares acquired under the Insulet Corporation Employee Stock Purchase Plan since the date of the filer's most recently filed Form 4. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 20:12 UTC | INSULET CORP PODD · Entity 3516 | Tax withholdingCommon Stock | 3,973 | $177.19 | $703,975.87 |
DisclosureSEC source: 0001127602-24-017652 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,599 F1 · shares: This transaction represents the withholding of shares received upon the vesting of restricted stock units to cover the associated tax obligations. Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 21:30 UTC | INSULET CORP PODD · Entity 3516 | Tax withholdingCommon Stock | 908 | $163.60 | $148,548.80 |
DisclosureSEC source: 0001127602-24-007622 · form4.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,572 F2 · shares: This transaction represents the withholding of shares received upon the vesting of restricted stock units to cover the associated tax obligations. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:30 UTC | INSULET CORP PODD · Entity 3516 | GrantStock Option (Right to Buy) · Derivative | 29,475 | $0.00 Strike: $166.62 | $0.00 |
DisclosureSEC source: 0001127602-24-007622 · form4.xml · derivative · entry 3 Hollingshead James · CIK 0001570610 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,475 Underlying: Common Stock · 29,475 shares Expires 2034-02-27 F3 · derivative.exercise_date: Annual Non-Qualified Stock Option ("Option") Award. The Options become exercisable in substantially equal installments on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:30 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 12,303 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-007622 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,480 F1 · shares: Annual Restricted Stock Unit ("RSU") award. RSUs vest in equal installments on each of the first, second and third anniversaries of the grant date and are settled in shares of common stock on a one-for-one basis. Read SEC document |
| August 28, 2023 Filed Aug 29, 2023 20:07 UTC | INSULET CORP PODD · Entity 3516 | PurchaseCommon Stock | 5,550 | $181.41 | $1,006,825.50 |
DisclosureSEC source: 0001127602-23-023341 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,177 F1 · price: The price reported represents the weighted average sale price of the shares purchased. The shares were purchased at varying prices in the range of $179.88 to $184.10. Specifically: 1,558 shares were purchased in the range of $179.88 to $180.81, with a weighted average share price of $180.47; 3,210 shares were purchased in the range of $181.00 to $181.98, with a weighted average share price of $181.41; 371 shares were purchased in the range of $182.16 to $183.08, with a weighted average share price of $182.76; and 411 shares were purchased in the range of $183.19 to $184.10, with a weighted average share price of $183.78. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:08 UTC | INSULET CORP PODD · Entity 3516 | Tax withholdingCommon Stock | 3,898 | $272.48 | $1,062,127.04 |
DisclosureSEC source: 0001127602-23-017516 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,627 F1 · shares: This transaction represents the withholding of shares received upon the vesting of restricted stock units to cover the associated tax obligations. F2 · balance_after: Includes 81 shares acquired under the Insulet Corporation Employee Stock Purchase Plan on May 31, 2023. Read SEC document |
| February 28, 2023 Filed Mar 1, 2023 22:37 UTC | INSULET CORP PODD · Entity 3516 | GrantEmployee Stock Option (Right to Buy) · Derivative | 16,475 | $0.00 Strike: $276.36 | $0.00 |
DisclosureSEC source: 0001127602-23-007982 · form4.xml · derivative · entry 2 Hollingshead James · CIK 0001570610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,475 Underlying: Common Stock · 16,475 shares Expires 2033-02-28 F2 · derivative.exercise_date: Annual Non-Qualified Stock Option ("Option") Award. The Options become exercisable in substantially equal installments on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| February 28, 2023 Filed Mar 1, 2023 22:37 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 6,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-007982 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,444 F1 · shares: Annual Restricted Stock Unit ("RSU") award. RSUs vest in equal installments on each of the first, second and third anniversaries of the grant date and are settled in shares of common stock on a one-for-one basis. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 20:33 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 21,699 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-016388 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,569 F1 · shares: Restricted Stock Unit ("RSU") award. RSUs vest in equal installments on each of the first, second and third anniversaries of the grant date and are settled in shares of common stock on a one-for-one basis. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 00:16 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,400 | $256.84 | $616,416.00 |
DisclosureSEC source: 0001127602-21-029962 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,721 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 18, 2021 Filed Nov 18, 2021 22:03 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 316 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-029558 · form4.xml · nonDerivative · entry 4 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,121 F4 · kind: Represents performance-based restricted stock units granted on July 1, 2020. The shares were earned on November 18, 2021, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| November 18, 2021 Filed Nov 18, 2021 22:03 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 1,393 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-029558 · form4.xml · nonDerivative · entry 3 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,805 F3 · kind: Represents performance-based restricted stock units granted on November 19, 2020. The shares were earned on November 18, 2021, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| November 17, 2021 Filed Nov 18, 2021 22:03 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 12,060 | $254.81 | $3,073,008.60 |
DisclosureSEC source: 0001127602-21-029558 · form4.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,412 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/14/2018. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 22:03 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 20,360 | $254.81 | $5,187,931.60 |
DisclosureSEC source: 0001127602-21-029558 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,472 F1 · kind: Represents performance-based restricted stock units granted on November 14, 2018. The shares were earned on November 16, 2021, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 19:05 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 4,100 | $259.47 | $1,063,827.00 |
DisclosureSEC source: 0001127602-21-029096 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,112 F1 · kind: Disposition to issuer for tax withholding on scheduled vesting of Restricted Stock Units granted for dates 11/14/2018, 11/21/2019 and 11/19/2020. F2 · balance_after: Includes 35.133 shares of ResMed stock purchased on October 29, 2021, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 00:56 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,400 | $264.35 | $634,430.40 |
DisclosureSEC source: 0001127602-21-028014 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,177 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 08, 2021 Filed Oct 12, 2021 22:21 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 234 | $246.52 | $57,685.68 |
DisclosureSEC source: 0001127602-21-026983 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,577 F1 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 07/01/2020. Read SEC document |
| October 01, 2021 Filed Oct 1, 2021 23:28 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,400 | $261.33 | $627,183.12 |
DisclosureSEC source: 0001127602-21-026355 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,479 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 19:01 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,400 | $287.30 | $689,526.96 |
DisclosureSEC source: 0001127602-21-024743 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,879 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 15:58 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 5,741 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-024089 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,279 F1 · kind: Represents performance-based restricted stock units granted on November 19, 2020. The shares were earned on August 19, 2021, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 19, 2021 Filed Oct 12, 2021 22:19 UTC Amendment | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 1,332 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-026982 · form4a.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,611 F2 · kind: Represents performance-based restricted stock units granted on July 1, 2020 and reportable back on August 19, 2021. The shares were earned when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 19, 2021 Filed Oct 12, 2021 22:19 UTC Amendment | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 5,741 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-026982 · form4a.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,279 F1 · kind: Represents performance-based restricted stock units granted on November 19, 2020. The shares were earned on August 19, 2021, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 02, 2021 Filed Aug 3, 2021 01:30 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,400 | $268.94 | $645,463.68 |
DisclosureSEC source: 0001127602-21-022817 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,538 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 15:59 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,400 | $247.30 | $593,513.04 |
DisclosureSEC source: 0001127602-21-021468 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,938 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 18:39 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,400 | $206.03 | $494,475.36 |
DisclosureSEC source: 0001127602-21-018674 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,338 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| May 27, 2021 Filed May 28, 2021 20:03 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 808 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-018304 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,870 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). RSUs vest in full on April 30, 2022 and are settled in shares of common stock on a one-for-one basis. Read SEC document |
| May 21, 2021 Filed May 24, 2021 15:13 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,400 | $202.01 | $484,824.00 |
DisclosureSEC source: 0001127602-21-017859 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,738 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · balance_after: Includes 92.27 shares of ResMed stock purchased on April 30, 2021, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 21:23 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 4,800 | $200.00 | $960,000.00 |
DisclosureSEC source: 0001127602-21-013699 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,046 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 01, 2021 Filed Feb 2, 2021 23:59 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,400 | $200.18 | $480,436.80 |
DisclosureSEC source: 0001127602-21-003568 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,846 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 18, 2021 Filed Jan 20, 2021 00:58 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 1,913 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-002065 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,246 F1 · shares: Represents performance-based restricted stock units granted on November 21, 2019. The shares were earned on January 18, 2021, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 21:52 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,400 | $211.09 | $506,613.60 |
DisclosureSEC source: 0001127602-21-000640 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,333 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 01, 2020 Filed Dec 2, 2020 00:37 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,400 | $210.97 | $506,330.40 |
DisclosureSEC source: 0001127602-20-030251 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,733 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 18:51 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 15,547 | $214.74 | $3,338,562.78 |
DisclosureSEC source: 0001127602-20-029544 · form4.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,133 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2017. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 18:51 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 26,246 | $214.74 | $5,636,066.04 |
DisclosureSEC source: 0001127602-20-029544 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,680 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2017. The shares were earned on November 17, 2020, when the compensation committee certified that the performance metrics were met. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 22:18 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 1,286 | $212.11 | $272,773.46 |
DisclosureSEC source: 0001127602-20-029007 · form4.xml · nonDerivative · entry 3 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,434 F4 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/21/2019. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 22:18 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 1,804 | $212.11 | $382,646.44 |
DisclosureSEC source: 0001127602-20-029007 · form4.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,720 F3 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/14/2018. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 22:18 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 2,135 | $212.11 | $452,854.85 |
DisclosureSEC source: 0001127602-20-029007 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,524 F1 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2017. F2 · balance_after: Includes 56.52 shares of ResMed stock purchased on October 31, 2020, through the ResMed Employee Stock Purchase Plan. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 00:54 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,400 | $195.00 | $467,995.68 |
DisclosureSEC source: 0001127602-20-028053 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,602 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 20:44 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,400 | $170.43 | $409,022.88 |
DisclosureSEC source: 0001127602-20-026298 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,002 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 01, 2020 Filed Sep 2, 2020 21:42 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,400 | $202.02 | $484,853.52 |
DisclosureSEC source: 0001127602-20-024651 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,402 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 13, 2020 Filed Aug 17, 2020 15:17 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 7,328 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-023638 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,802 F1 · kind: Represents performance-based restricted stock units granted on November 21, 2019. The shares were earned on August 13, 2020, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 03, 2020 Filed Aug 4, 2020 21:32 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,400 | $202.02 | $484,853.52 |
DisclosureSEC source: 0001127602-20-022720 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,474 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 15:14 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,400 | $189.63 | $455,111.52 |
DisclosureSEC source: 0001127602-20-021091 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,874 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.